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Modulation of growth factors by growth hormone in children with
chronic renal failure. Anthropometric measurements and circulating
growth factors were studied serially in 44 prepubertal children with growth
failure and chronic renal failure (GFR = 10 to 40 mI/min/1.73 m2) who
were randomized to receive either recombinant human growth hormone
(rhGH; N = 30) or no treatment (N = 14). RhGH was given as Nutropin,
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0.05 mg/kg/day, and the studies were carried out at baseline and after 3
and 12 months. At baseline, serum insulin-like growth factor binding
protein (IGFBP)-1 and -2 levels were, while IGFBP-3 levels were not,
higher than those of children with normal renal function. In addition,
height SDS at baseline correlated inversely with serum IGFBP-2 levels
(r =
—0.461, P = 0.0016), but did not correlate significantly with any other
factor. After 12 months of study, the 30 children receiving rhGH showed:
(i) greater increase in height (9.1 2.8 vs. 5.5 1.9 cm, P < 0.0001); (ii)
increases in serum levels of IGF-I, IGF-II, free IGF-I, IGFBP-3 and acid
labile subunit (ALS); (iii) a greater decrease in serum IGFBP-1 levels; and
(iv) no significant difference in serum IGFBP-2 levels, when compared to
the 14 control patients. The change in height SDS after 12 months of
rhGH (+ 0.8) in the 30 treated children correlated significantly and
positively with serum ALS, IGFBP-3, total IGF, IGF-I, IGF-II and free
IGF-I levels measured during treatment. These observations suggest that,
in children with growth failure associated with chronic renal failure: (i)
IGFBP-2, and not IGFBP-3, is likely to be a growth inhibitor; (ii) rhGH
stimulates catch-up growth in part by increasing serum levels of IGF
peptides; and (iii) linear growth is influenced by the balance between
growth stimulating IGFs and growth inhibitory IGFBPs.
Many children with chronic renal failure do not achieve an
adult height that is consistent with their genetic potential despite
aggressive therapy with calorie supplements, alkali, phosphate
binders, 1,25 dihydroxyvitamin D, dialysis, and transplantation [1],
In order to explain this growth failure, investigators first focused
on the growth hormone (GH)/insulin-like growth factor (IGF)!
growth plate chondrocyte (GPC) axis, which plays a central role in
linear growth. GH increases local IGF-I production by stimulating
GPCs [1, 2] and increases serum IGF-I levels by stimulating
hepatic IGF-I production. GH and IGF are known to act in
synergy to stimulate proliferation and hypertrophy of GPCs, and
circulating IGF-I has now been shown to stimulate linear growth
in rats and humans [3—5]. However, despite the severe growth
failure seen in many CRF children, initial studies found their
serum GH and IGF levels to be normal or high, suggesting that
abnormalities of this axis were not responsible for the growth
failure [1, 6—8].
A number of recent findings suggested a more prominent role
for the GH/IGF/GPC axis in the growth failure of CRF. First,
although serum levels of IGF are normal, IGF-I bioavailability is
decreased in CRF serum [7—10]. Second, a family of six IGF
binding proteins (IGFBPs) with high affinity for IGF peptides has
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been identified [11, 12] and levels of many of these IGFBPs are
elevated in CRF serum [8, 10, 13—2 1]. Some investigators consider
that this excess of IGFBPs leads to the decreased bioavailability of
IGF-I. Third, treatment of growth retarded CRF children with
recombinant human growth hormone (rhGH) has resulted in
impressive catch-up growth [15, 17, 22]. This rhGH-induced
catch-up growth has been attributed, at least in part, to the rise in
serum IGF-I found in these children [15, 17, 22]. Previous studies
have concluded that, of all the IGFBPs found in excess in CRF
serum, IGFBP-3 was most likely to impair IGF action since it is by
far the most common serum IGFBP [10, 15, 231. In contrast, the
roles of other IGFBPs and of IUF-Il, in both the growth failure
and the catch-up growth associated with rhGH treatment of these
children, have not been emphasized.
The present report describes the serum levels of a number of
GH/IGF axis proteins obtained from a large population of
children with CRF and growth failure who entered a prospective
study that was designed to evaluate the effect of rhGH on growth
and renal function in such children. The effects on renal function
will be reported elsewhere. Strict entry and exclusion criteria
which were employed in this study, particularly the requirement
for a GFR between 10 and 40 ml/min/1.73 m2 and the exclusion of
other conditions that have been associated with growth failure,
suggest strongly that the growth failure and abnormalities of
serum growth factor levels noted in our patients at baseline were
due to CRF and not to other causes, The study examined the
effect of rhGH therapy on the growth of CRF children and related
these changes in growth to changes in serum levels of growth
factors. These results suggest that abnormal regulation of
IGFBP-2 and perhaps IGFBP-1 contributes to the growth failure
of CRF, whereas IGFBP-3 is probably not a major growth
inhibitor in these children. In addition, the data suggest that
changes in the levels of IGF-I, free IGF-I, IGF-II, IGFBP-1,
IGFBP-3 and acid-labile subunit (ALS) may contribute to the
catch-up growth that occurs when these children are treated
successfully with rhGH.
Methods
Patients
Sixty-nine children (84% male) with CRF were enrolled from
26 participating centers into a prospective controlled study of
growth hormone treatment. The study was approved by the
Institutional Review Board for Research Involving Human Sub-
jects of each participating center, and written, informed consent
was obtained from the parents of each child. Inclusion criteria
were as follows: (1) irreversible renal insufficiency [glomerular
filtration rate (GFR)> 10 and <40ml/min/1.73 m2]; (2) height <
5th percentile for chronologic age; (3) age > 2.5 years; (4) ability
to stand for height measurement; (5) bone age < 10years for girls,
< 11 years for boys; and (6) Tanner stage 1. Exclusion criteria
included: (1) serum albumin < 2.5 g/dl; (2) receiving medications
which influence growth; (3) presence of illnesses which affect
growth; (4) diabetes mellitus; and (5) presence or past history of
malignancy.
Of the 69 children who entered the main study, 20 exited in the
first year. Of these, 12 reached end-stage renal disease (7 required
dialysis, 5 received a renal transplant), 6 entered puberty, 1 had an
allergic reaction to rhGH injections, and 1 died of drowning. Five
of the remaining 49 children who completed the first year of study
(1 untreated and 4 treated) had insufficient serum for the 0 and 12
month protein assays. Hence, 44 of the 69 patients who entered
the main study form the patient population for the present report.
An additional 10 healthy prepubertal children (8 of 10 male; mean
age 7.4 2.7 years) provided serum samples which served as
control values for serum IGFBP-2 and IGFBP-3 measurements,
Study design
In this open-label, multicenter study, children were randomized
such that one-third were entered as untreated controls and
two-thirds were entered to receive rhGH; these two groups were
balanced for age, gender, height, GFR at baseline, and primary
renal disease (congenital, acquired or metabolic). Parents of
treated children were trained to administer a daily subcutaneous
dose of 0.05 mg/kg rhGH (Nutropin®, Genentech, Inc. South San
Francisco, CA, USA) from 5 mg vials which were reconstituted
with 1 ml bacteriostatic water. After the baseline visit, children
were re-evaluated every three months. The dose of drug was
adjusted at each visit to keep the dose/kg relationship equal to
0.05 mg/kg/day.
Anthropometric measurements and bone age
Anthropometric measurements were obtained for each child at
0, 3, and 12 months. Height was measured in each center by one
observer using the same wall-mounted stadiometer. Mid-arm
muscle circumference (MAMC) and triceps skinfold thickness
(TSF) were measured on the dominant arm. Bone age was
determined by a left hand and wrist radiograph at 0 and 12
months.
Serum protein assays
All CRF children fasted for at least five hours prior to blood
drawing, whereas the 10 control children were not fasted. Note
that the measurements of IGFBP-2 and IGFBP-3 which were
compared between the CRF and control groups of patients are
not affected by the fasting status of an individual. Blood was
centrifuged and the serum samples frozen (—80°C) until assay.
IGF-I and IGF-II were separated from their binding proteins by
acid chromatography [7] and then measured by radioimmunoas-
say (RIA) [20, 241. IGF-I antiserum was provided by Drs. L.E.
Underwood and J.J. van Wyk (Chapel Hill, NC, USA) through
the National Hormone and Pituitary Program. IGF-II antibody
was purchased from Amano International Enzyme Co. (Troy, VA,
USA).
IGFBP-1, IGFBP-3, free IGF-I, and insulin were measured by
IRMA [21], using commercially available kits (Diagnostic Systems
Laboratories, Webster, TX, USA). IGFBP-2 was measured by
RIA using IGFBP-2 antiserum kindly provided by Dr. Werner
Blum [19]. Recombinant human IGFBP-2 (purchased from Aus-
tral, San Ramon, CA, USA) was used for the standard curve (1 to
100 ng/ml) and also for iodination which was carried out by a
modification of the chloramine-T method [71. Labeled IGFBP-2
was recovered by chromatography on a Sephadex G-75 column.
Normal sera were diluted 1:5 and sera from patients with CRF
were diluted 1:10 in RIA buffer (40 m Na phosphate, pH 7.4, 120
mM NaCI, 0.5% BSA). Samples and standards were preincubated
with anti-IGFBP-2 antiserum (1:2000 final concentration) for one
hour at room temperature. After addition of labeled IGFBP-2
(20,000 cpm/tube), incubation was carried out overnight at 4°C.
Bound and free ligand were separated by precipitation with
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Table 1. Clinical and anthropometric measurements at baseline in children with chronic renal failure (CRF) and changes resulting from 12 months
of treatment with GH
CRF-rhGH patients (N = 30) CRF-no rhGH patients (N = 14) Difference in
degree of changeChanges from Changes from
Characteristics Baseline 0—12 months Baseline 0—12 months between groups
Male 83% 86%
GFR ml/min/1.73 m2 27.5 8.9 27.6 8.8
Age years 5.6 2.0 5.7 2.6
Bone age years 4.0 1.5' 1.0 0.3 4.2 1.8 0.9 0.4c P = 0.5282
Height SDS —2.7 0.7 0.8 0.5 —2.7 0.8 0.0 0.3 P < 0.0001
Weight for height SDS 0.0 1.3 0.4 0.7 —0.2 1.5 0.4 0.5 P = 0.8703
MAMC cm 14.1 1.6" 1.2 0.9" 14.4 2.8 —0.2 1.7c P = 0.0015
TSFmm 7.9 3.2" —1.9 2.5" 8.5 3.2 0.9 1.2" P = 0.0003
Abbreviations are: MAMC, mid-arm muscle circumference; TSF, tricep skin fold thickness; CRF, chronic renal failure.
N = 27
hN = 29
"N = 13
second antibody (ICN, Costa Mesa, CA, USA) followed by 6%
polyethylene glycol.
Growth hormone binding protein (GHBP) was measured by
ligand-mediated immunofunctional assay [25]. ALS was measured
by RIA [261; purified ALS [27] was used for the standard curve
and also for iodination.
Statistics
Data are presented as mean SD butconverted to log 10 values
for statistical analysis. Differences within untreated and rhGH-
treated CRF groups at 3 and 12 months, between these two
groups at baseline, and between all CRF and control children at
baseline, were evaluated for significance by Student's f-test,
Differences between untreated and rhGH-treated CRF groups at
3 and 12 months were evaluated for significance by analysis of
covariance (ANCOVA). For all comparisons, differences were
considered significant when P 0.05. Pearson correlation coeffi-
cients were calculated for correlating variables measured: (a) in
all CRF children at baseline; and (b) in rhGH-treated CRF
children during the treatment phase of the study, using the mean
of the 3- and 12-month values for each variable. When correlating
variables measured in all CRF children during the treatment
phase of the study, Pearson partial correlation coefficients were
calculated using the mean of the 3 and 12 months values for each
variable. The effect of multiple variables on the change in height
SDS between 0 and 12 months of rhGH treatment were evaluated
by multiple regression analysis.
Results
Anthropometrics and bone age
Some of the baseline characteristics of the 30 patients in the
rhGH treatment group and the 14 in the untreated group are
presented in Table 1. Children receiving rhGH grew 9.1 2.8 cm
and gained 3.5 1.5 kg in weight during the first 12 months of
rhGH treatment, while untreated children grew 5.5 1.9 cm
(difference between groups, P = 0.0001) and gained 2.2 1.0 kg
(difference between groups, P = 0.007) over the same period of
time, This increased growth in the rhGH group was not associated
with any acceleration in bone age. The treated children also
showed a greater gain in MAMC during the first 12 months of
rhGH than did the untreated children. In contrast, weight stan-
dardized for height and gender increased at a similar rate in both
Table 2. Baseline levels of serum growth factors in children with CRF
Characteristics
All patients
(N = 44)
CRF-rhGH
patients
(N = 30)
CRF-no rhGH
patients(N = 14)
IGF-I nM 14 9 15 10 10 5
IGF-I SDS —0.9 1.2 —0.7 1.3 —1.2 1.0
Free IGFIpMd 95 73" 71 41b 141 94"
IGF-II nM 100 34 100 29 101 41
IGF-II SDS 1.2 1.2 1.2 1.2 1.1 1.3
InsulinpM" 30 43 19 14 52 66
Total IGF nM 114 38 115 34 111 45
IGFBP-1 nM 18 14 18 9 17 21
IGFBP-1 SDS 2.3 0.9 2.4 0.6 2.1 1.4
IGFBP-2 nM' 50 20 50 17 51 26
IGFBP-3 nM5 124 45 130 50 109 25
IGFBP-3 SDS" 1.4 1.8 1.7 2.0 0.7
ALS nM 199 72 207 81 179 40
GHBPpM 179 102' 183 104 144 104'
GHBP SDS 0.3 1.6 0.4 1.7 0.0 1.3'
a = 26
hN = 17
"N =9
'-' CRF-rhGH different from no rhGH patients (P = 0.029)
CRF-rhGH different from no rhGH patients (P = 0.021)Values > normal range (22 11), P < 0.001gValues not different from normal range (98 17)
h Values > normal range (—0.2 0.7) P = 0.013N = 42
N = 12
the rhGH-treated and untreated groups. Relative to baseline, TSF
values were slightly greater after 12 months of study in the
untreated children but were significantly less in the children
treated with rhGH.
IGF-I, free IGF-I, IGF-II and insulin levels
At baseline in the 44 CRF children, IGF-I levels were lower
than normal, —0.9 1.2 SDS, while IGF-II levels were higher
than normal, 1.2 1.2 SDS. Levels of IGF-I and IGF-II did not
differ between treated and untreated groups at baseline while
insulin and free IGF-I levels were higher in the untreated group
(Table 2). Children treated with rhGH for 3 and 12 months had
higher serum levels of IGF-I, IGF-II and insulin relative both to
baseline values and to levels in the untreated group; IGF-I rose to
0.2 1.0 SDS and IGF-II levels rose to 2.1 1.3 SDS after 12
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months of rhGH (Figs. 1 and 2). Children treated with rhGH for
3 and 12 months had higher serum levels of free IGF-I relative to
baseline values, and their free IGF-I levels were higher than those
of the untreated children after 12 months (Fig. 2). Untreated
children had serum levels of IGF-I, free IGF-I, IGF-II and insulin
at 3 and 12 months of study that were not different from baseline
values.
IGFBP-1 and IGFBP-2 levels
Serum IGFBP-1 levels were increased in the 44 CRF children at
baseline, measuring 2.3 0.9 SDS (Table 2). Baseline IGFBP-2
levels in these 44 children (50 20 nM) were high relative to 10
healthy prepubertal children (22 11 ni). IGFBP-1 and -2 levels
did not differ between treated and untreated groups at baseline.
As shown in Figure 3, CRF children treated with rhGH for 3 and
12 months had lower serum levels of IGFBP-1 relative both to
baseline values and to levels in the untreated group. Serum
IGFBP-2 levels did not differ between the rhGH-treated and
untreated groups of CRF children after 3 and 12 months of study;
however, IGFBP-2 levels in the rhGH group after 12 months of
treatment were slightly lower than baseline values. Untreated
CRF children had no change in serum IGFBP-1 or IGFBP-2
levels at 3 and 12 months of study.
IGFBP-3 and ALS levels
Baseline IGFBP-3 levels in the CRF children tended to be
higher than age- and gender-matched normal values, measuring
1.4 1.8 SDS. As shown in Table 1, this SDS was greater than the
—0.2 0.7 SDS for IGFBP-3 levels in the 10 control children;
nevertheless, n levels of IGFBP-3 were not different between the
10 control children and the 44 CRF children at baseline. IGFBP-3
levels did not differ between treated and untreated CRF groups at
baseline. As shown in Figure 4, children treated with rhGH for 3
and 12 months had higher serum levels of IGFBP-3 and ALS
relative both to baseline values and to levels in the untreated
group; IGFBP-3 levels rose to 4.0 3.2 SDS after 12 months of
0 3 12 0 3 12
rhGH NorhGH
Fig. 2. Insulin and free IGF-I levels at 0, 3, and 12 months of study. Insulin
and free IGF-I levels were measured in 30 rhGH-treated CRF children
(rhGH) and 14 untreated CRF children (no rhGH) as described in the
Methods section. 'Different from no rhGH, t-test, P < 0.03. 2Different
from baseline, t-test, P < 0.0005. 3Different from no rhGH, ANCOVA,
P < 0.017. 4Different from no rhGH, ANCOVA, P = 0.0464.
rhGH, and were hiher than total IGF levels at each time point. In
contrast, untreated children had no change in levels of either
IGFBP-3 or ALS at 3 and 12 months of study.
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Fig. 1. JGF-I and IGF-II levels at 0, 3, and 12
months of study. IGF-I and IGF-II levels were
measured in 30 rhGH-treated CRF children
(rhGH) and 14 untreated CRF children (no
rhGH) as described in the Methods section.
Normal IGF-I and IGF-II SDS values for age
and gender were based on published data using
these specific RIAs [28]. 'Different from
baseline, t-test, P < 0.006. 2Different from no
rhGH, ANCOVA, P < 0.006.
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Fig. 3. IGFBP-1 and IGFBP-2 levels at 0, 3, and 12 months of study. IGFBP-1 and IGFBP-2 levels were measured in 30 rhGH-treated CRF children
(rhGH) and 14 untreated CRF children (no rhGH) as described in the Methods section. Normal IGFBP-l SDS values for age were provided by the
manufacturer of the IGFBP-I IRMA (DSL) and were based on levels measured in 144 fasting children from 2 to 12 years of age. 'Different from
baseline, t-test, P < 0.0002. 2Different from no rhGH, ANCOVA, P < 0.017. 3Different from baseline, t-test, P = 0.0496.
Fig. 4. IGFBP-3, ALS, and total IGF levels at 0,
3, and 12 months of study. IGFBP-3, ALS, and
total IGF levels were measured in 30 rhGI-I-
treated CRF children (rhGH) and 14 untreated
CRF children (no rhGH) as described in the
Methods section. Normal IGFBP-3 SDS values
for age and gender were provided by the
manufacturer of the IGFBP-3 IRMA (DSL)
and were based on levels measured in 281
children from 2 to 11 years of age. 'Different
from baseline, t-test, P < 0.0006. 2Different
from no rhGH, ANCOVA, P < 0.011.
GHBP levels
At baseline in the CRF children, GHBP levels were not
different from normal, measuring 0.3 1.6 SDS, nor did they
differ between treated and untreated groups. As shown in Figure
5, GHBP levels did not change at 3 or 12 months of study in either
the untreated or the rhGH-treated children.
Variables influencing height
As shown in Figure 6, height SDS at baseline correlated
inversely with serum IGFBP-2 levels in the CRF children studied
(r =
—0.461, P = 0.0016). No other variable tested correlated
significantly with baseline height SDS. In the children treated with
rhGH, the change in height SDS between 0 and 12 months [height
SDS at 12 months minus height SDS at 0 months or z height SDS
(0 — 12)1 correlated most strongly with levels of ALS (r = 0.57, P
= 0.0011), IGFBP-3 (r = 0.55, P = 0.0017), and total IGF (r =
0.49; P < 0.0062) measured during treatment (Fig. 6). Multiple
regression analysis found a relationship between height SDS
(0 — 12) and treatment levels of both IGFBP-3 and total IGFs(r = 0.59) that was similar to the relationship between height
SDS (0 — 12) and each variable analyzed independently. In
contrast, the untreated CRF children showed no correlation
between height SDS (0 — 12) and serum levels of either ALS(r = 0.10, P = 0.7424), IGFBP-3 (r = 0.00, P = 0.7649) or total
IGF (r =
—0.24, P = 0.4155). As shown in Table 3, z height SDS
(0 — 12) also correlated with levels of IGF-I, free IGF-I, and
IGF-1I, and with ALS (0 — 12) and z IGFBP-3 (0 — 12), in the
rhGH- treated children but not the untreated children.
Variables influencing free IGF-J levels
At baseline, free IGF-1 levels showed a significant inverse
correlation with IGFBP-1 levels (r =
—0.59, P = 0.0018) but did
not correlate with either IGF-I or IGFBP-2 levels. When free
IGF-1 levels were compared to levels of the other serum proteins
40
30
20
1,2
8
60
40
3
C\I
U-C
C')0
U-C
0312 0312
rhGH
250
200
1,2
1,2
8 1,2
CJ)6 1
150
100
50
0
C0
IL 2
0
400 1,21,2
II:
C
c
250
200
150
100
50
0 0
No rhGH
300
200
-J< 100
0 3 12 0 3 12
rhGH No rhGH
1,2
1,2
0312 0312
rhGH NorhGH
0312 0312
rhGH NorhGH
,)
(0
Cf)4
(9
 0312
r  r
:
200
SPNSG: Growth factors in children with renal failure 1975
hypophysectomized rats [4, 29, 30]. In the present study, baseline
IOF-! levels in CRF serum were in the low-normal range while
serum IGF-lI levels were in the high-normal range, similar to past
measures of serum IOF levels by RIA in humans and rats with
CRF [7,8, 15. 17, 31].
Increased IGF binding activity is a hallmark of CRF serum [7,
8, 10, 15, 32] and, when combined with normal IGE levels,
explains the low IGF bioactivity of CRF serum in cartilage
bioassay systems [9, 10, 15]. The increased IGF binding activity is
due to excess ICiFBPs; IGFBPs-1, -2, and -3 levels are reported as
elevated in CRF serum, and levels of other IOFBPs may also he
high [10, 13—20]. In this study, serum IGFIJP-J levels were higher
than established normal values, measuring 2.3 0.9 SDS, and
serum IGFBP-2 levels were higher than in healthy control chil-
dren. IOFBP-1 and -2 are -28 and -33 kDa proteins, respectively,
which are major contributors to the serum pool of unsaturated
IGFBPs [8, 14, 18]. IGFJ3P-l and -2 inhibit JOE action in vitro [18,
33, 34]. Of relevance here is that ICIFBP-1 inhibited both basal
and IGF-I stimulated growth of chick embryo pelvic cartilage in
__________________
organ culture [33]. IGFBP-1 also blocks growth in viva; IGFBP-1
injected into hypophysectomized rats inhibited OH- or IOF-T-
stimulated weight gain and tibial epiphyseal widening [4]. This last
study shows that circulating IOFBP-l can inhibit growth and
suggests that an excess of any IGFBP which binds IGF-1 and -IT
with an affinity comparable to that of IOFBP-1 can inhibit OH- or
tOE-I-stimulated cartilage growth.
lCIFlJP-3 is the major serum IOFBP of healthy individuals,
where it is found primarily in the --150 kDa serum complex hound
to one lOF peptide and to one ALS protein [16, 27, 35] lC,FBP-3
can inhibit growth and TOE-I action in cultured fibroblasts, but
under sonic conditions IGFBP-3 potentiates IGF-l action [36—
38]. Past studies reported that IGFBP-3 levels were quite high in
CRF and proposed that IGFBP-3 is the major inhibitor of IGF
action in CRF serum [10. 15, 23]. However, in the present study,
serum [OFBI'-3 levels were not significantly higher than those
from healthy control children. The likely explanation for the
discrepancy in IGFBP-3 levels among studies is that many chil-
dren in past studies required dia]ysis, whereas all 44 children
studied here had significant residual renal function. It is important
tn note, however, that all 44 were also growth retarded, suggesting
that serum IGFBP-3 is not a major contributor to this growth
failure. Indeed, height SDS at baseline did not correlate signifi-
cantly with IGFBP-3 levels, similar to findings from Tonshoff et al
[39]; instead, both Tonshoff et al and the present study found that
height SDS at baseline correlated significantly and inversely with
levels of IOFBP-2, the most abundant IGFBP in the 35 kDa CRF
serum fractions, suggesting that IOFBPs other than IGFBP-3 are
the major inhibitors of bE-mediated growth in CRF serum. The
fact that IGFBP-1 and -2 bind ICE peptides with roughly compa-
rable affinities [40] is consistent with the possibility that JGFBP-2
is a growth inhibitor in CRF.
Serum OHBP levels are elevated in rats with experimental
uremia [41]. However, serum OHBI levels were not different from
normal in the GRE children studied here, indicating that Gi HIP does
not play a signilicant role in the growth failure of GRE.
GH/JGF axis proteins and growth during rh Gil treatment
The linear growth of GRE children during the 12 months of this
study was significantly greater in the rhGl-J treated group, consis-
tent with the catch-up growth reported in past controlled [17] and
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Fig. S. (J1-IBP levels at 0, 3, and 12 months of study GHBP levels were
measured in 30 rhGH-treated CRF children (rhGI-1) and t4 untreated
CRF children (no rhOH) as described in the Methods section. Normal
GHBP SDS values for age and gender were based on published data using
this specific MA [25]. 'N = 12.
in all 44 patients during the treatment phase of the study, free
[OF-I levels correlated significantly with levels of ICE-I (r = 0.54,
P = 0.0082) hut not with levels of IGFBP-1 or IGFBP-2.
Variables influencing JGFBP-l levels
As shown in Figure 7, IGFBP-1 levels showed a significant
inverse correlation with insulin levels (r =
—0.47,1" = 0.012). but
no significant correlation with tOE-I, iCE-H or total ICE levels, at
baseline. IGFBP- 1 levels were also compared to those of the other
serum proteins in all 44 patients during the treatment phase of the
study. This analysis showed that JGFBP-1 levels: (i) correlated
significantly with insulin levels (r = - 0.39, P = 0.0101); (ii)
correlated significantly with TOE-I levels (r —0.43, P = 1)0036);
and (iii) did not correlate significantly with ICE-Il or total ICE
levels.
Discussion
The findings in our study confirm the salutary effect of growth
hormone in children with CRF and growth failure. We have also
confirmed that the serum Levels of a number of GH/IOF/ICFBP
axis proteins in CRF children are abnormal and have studied their
relationship to growth failure in these children. Serum ICE levels
were studied closely since exogenous TOE-I stimulates linear
growth in children with primary (il-I receptor deficiency' [5], and
since lGF-I and lOF-Il can each stimulate linear growth in
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Fig. 6. Correlation of IGFBP-2, IGFBP-3, ALS, and total IGF levels with height. Correlations between: A. IGFBP-2 and height SDS in all 44 CRF
children at baseline. B. ALS levels (mean of 3 and 12 months values) and the change in height SDS between 0 and 12 months of study [ height, SDS
(0 — 12)1 in the 30 rhGH-treated CRF children. C. IGFBP-3 levels (mean of 3 and 12 month values) and z height SDS (0 — 12) in the 30 rhGH-treated
CRF children. D. Total IGF levels (mean of 3 and 12 month values) and height SDS (0 — 12) in the 30 rhGH-treated CRF children.
uncontrolled [15, 22, 42—45] trials of rhGH therapy in this
population. The apparent increase in muscle mass and decrease in
fat stores in the group treated with rhGH has also been reported
previously in the CRF population [15, 43, 44].
The serum GH/IGF/IGFBP axis proteins were analyzed for
their role in the rhGH-mediated catch-up growth of CRF chil-
dren. A significant rise in IGF-I levels was reported in past
controlled [17] and uncontrolled [15, 23, 44, 45] studies of rhGH
in CRF. A rise in IGF-II levels with rhGH treatment was also
reported in past studies. This rise, although not always statistically
significant, was usually comparable on a molar basis to the rise in
IGF-I [15, 17, 23]. In the present study, rhGH treatment led to a
significant rise in serum levels of both IGF-I and -II, and to a
significant positive correlation between IGF levels and height
gain, suggesting a possible role for each IGF peptide in rhGH-
induced catch-up growth.
In body fluids, IGFs are bound by IGFBPs. Nevertheless, a pooi
of accessible IGFs must exist that mediates IGF effects by binding
to cell surface IGF receptors. The free IGF-l assay measures
serum IGF-I which binds to antibody coating the assay tube;
hypothetically, IGFBPs with lower affinity for IGF-I release IGF-I
to the antibody. In the present study, rhGH treatment increased
the serum pool of free IGF-I, suggesting that rhGH makes more
IGF-I accessible to the antibody or, in vivo, to the IGF receptor.
The positive correlation between free IGF-I levels and height gain
suggests a role for free IGF-I in rhGH-induced catch-up growth.
In addition, the inverse correlation between free IGF-I and
IGFBP-1 levels at baseline suggests a possible role for IGFBP-1 in
regulating IGF-I access to IGF receptors.
Between 0 and 12 months of rhGH treatment, serum IGFBP-I
levels fell 50%, similar to past results [17]. Hepatic IGFBP-l
expression and serum levels are strongly influenced by insulin, a
A
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Table 3. Correlations between change in height SDS (0 — 12 months)
and serum levels of growth factors/inhibitors
Characteristics CRF-rhGH pts CRF-no rhGH pts
IGF-I, mean of 3 & r = 0.47, P = 0.0085 r = —0.03
12 month levels P = 0.9149
IGF-II, mean of 3 & r = 0.43, P = 0.0172 r = —0.27
12 month levels P = 0.3540
Free IGF-I, mean of 3 & r = 0.49, P = 0.05 r = 0.28
12 month levels P = 0.5052
IGFBP-1, mean of 3 & r =
—0.07, P = 0.7142 r = 0.12
12 months levels P = 0.6711
IGFBP-2, mean of 3 & r = 0.00, P = 0.9893 r = —0.16
12 month levels P = 0.5949
LALS (0—12 months) r = 0.38, P = 0.0381 r = 0.13P = 0.6480
IGFBP-3 (0—12 months) r = 0.49, P = 0.0059 r = 0.03P = 0.9161
Total IGF r = 0.27, P = 0.1580 r = —0.24
(0—12 months) P = 0.4011
potent inhibitor of hepatic IGFBP-1 transcription in vitro and in
vivo [18, 46, 47]. The inverse relationship between insulin and
IGFBP-1 levels at baseline and during rhGH treatment suggests
that insulin is a major regulator of IGFBP-1 levels in CRF
children and may mediate the inhibitory effect of rhGH on
IGFBP-1 levels in these children. The fall in IGFBP-1 levels with
rhGH treatment is consistent with a role for IGFBP-1 as a growth
inhibitor in CRF.
In the present study, IGFBP-3 and ALS levels rose with rhGH
treatment and showed significant positive correlations with height
gain; the rise in IGFBP-3 level was also noted in other studies of
CRF children, although the rise was often not statistically signif-
icant [15, 17, 23], Both at baseline and during rhGH treatment,
ALS levels appear more than sufficient to combine with the
available IGFBP-3 and IGFs to form the 150 kDa serum complex.
Since, during rhGH treatment, levels of the three components of
the 150 kDa complex not only rose but began to correlate directly
and comparably with height gain, it is possible that serum levels of
this complex rise with rhGH treatment of CRF children and that
the ALS, IGFBP-3 and IUF proteins in this complex somehow
participate in the rhGH-induced catch-up growth.
Since rhGH increases serum IGF-I SDS more than IGFBP-3
SDS in CRF children, it has been argued that IGFBP-3 inhibits
growth in CRF by binding IGF-I and that the inhibitory effect of
rising IGFBP-3 levels during rhGH treatment is overcome by a
greater rise in levels of the growth stimulator IGF-I [15, 17, 23].
However, a more appropriate way to examine this issue is to
compare molar concentrations of IGF-I and IGFBP-3, which bind
in a 1:1 stoichiometry. On a molar basis, IGFBP-3 was in excess of
IGF-I at baseline and rose much more than IGF-1 in the present
study and in each of these past studies [15, 17, 23]. Even if one also
considers IGF-II, which (i) is the major serum JGF on a molar
basis, (ii) rose with rhGH therapy in each study, and (iii) can be
a significant growth stimulator in vivo [301, the baseline level and
molar increase of IGFBP-3 was still greater than that for the sum
of IGF-I and -II in prior studies [15, 17, 23]. In the present study
also, baseline IGFBP-3 (130 nM) exceeded total IGF (115 nM) and
the rhGH-induced increase of IGFBP-3 (62 nM) exceeded that of
total IGF (49 nM). If one further includes the significant levels of
IGFBP-1 and -2, it is clear that a marked surplus of IGFBPs over
0204060 80 100
IGFBP-1, flM
Fig. 7. Correlation between IGFBP-J and insulin levels in all 44 CRF
children at baseline.
IGF peptides exists at both 0 and 12 months of study. This
suggests that a significant amount of IGFBP-3 in CRF serum is
not bound to IGF peptides.
Based on the negative correlation of IGFBP-2 with height SDS
at baseline, this IGFBP may play a special role in blocking the
growth of untreated CRF children. Nevertheless, the correlation
of rhGH-induced height gain with levels of IGFs, IGFBP-3 and
ALS, rather than with IGFBP-1 or -2, suggests that the rhGH-
induced effect on the IGFIIGFBP axis, which is likely to contrib-
ute most to the catch-up growth of CRF children, is the rise in
IGF levels. Thus, the GH-induced increase in growth-stimulating
IGFs appears to overcome the inhibitory effects of IGFBP-2 and,
perhaps, other IGFBPs. In the final analysis, the steady state
among IGF-I, IGF-II, ALS and all of the IGFBPs will have to be
considered in order to understand the affects of CRF, and of GH,
on the growth of CRF children. However, it is impossible to
completely understand the role of IGFs, IGFBPs and related
proteins in the growth process by taking into account only their
serum concentrations. These proteins also have specific interac-
tions, for example when IGFs, IGFBP-3 and ALS form and
maintain the 150 kDa serum complex. Thus, insights gained from
serum levels must be tempered with additional studies exploring
the function of IGFs, IGFBPs and related proteins in CRF serum.
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